Overweight and obese patients less likely to achieve remission in early RA

June 14, 2013

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that overweight and obese patients are less likely to achieve successful remission in early rheumatoid arthritis (ERA) compared to those of normal weight.

Obese and overweight ERA subjects required 2.4 times more anti-TNF therapy throughout the study than normal weight participants without achieving similar outcomes.

RA is a chronic, inflammatory autoimmune disease affecting approximately 1 in 100 people worldwide. RA can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, workability, quality of life and life expectancy. At least 50% of RA patients in developed countries are unable to hold down a full-time job within 10 years of onset.2

Obesity continues to remain one of the greatest public health challenges of the 21st century; numbers of those affected rise each year, with the disease now causing 10% of deaths in Europe.3

"Obesity and are both on the rise, with devastating effects on individuals and society as a whole. These data reinforce the link between obesity and inflammation, and establish that BMI is one of the few modifiable variables influencing the major outcomes in RA," said Elisa Gremese, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome. "There is an urgent need to address the issues of to improve patients' chance of successful remission."

346 ERA patients with symptom duration <12 months were categorized into one of three BMI classes (normal weight, overweight and obese) and treated according to a treat-to-target strategy aimed at remission. The strategy included strict follow-up visits, treatment with methotrexate up to 25mg/week+steroids, and combination with a TNF blocker if at least a good response according to EULAR criteria* was not obtained.

Data demonstrate that overweight and reached a lower rate of remission, both with DAS and CDAI‡ criteria, at 6 and 12 month follow-up visits. A higher percentage of obese and overweight ERA patients were under anti-TNF treatment after 12 months of follow-up compared to normal weight.

Explore further: 50 percent of rheumatoid arthritis patients discontinue medication within the first two years

More information: * EULAR response criteria; individual patients classified as non-, moderate, or good responders, dependent on the extent of change and the level of disease activity reached

‡ DAS, Disease Activity Score; clinical index of RA disease activity that combines information from swollen joints, tender joints, the acute phase response and general health. CDAI is a composite index (without acute-phase reactant) for assessing disease activity and is based on the summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS scale for estimating disease activity

1.Gremese AL et al., The body mass index: a determinant of remission in early rheumatoid arthritis [abstract]. EULAR Annual European Congress of Rheumatology; 12-15 June 2013; Madrid, Spain. Abstract nr. OP0178.

2.Chronic diseases and Health Promotion: Chronic Rheumatic Conditions, World Health Organisation. Available from: www.who.int/chp/topics/rheumatic/en/. Last accessed: May 2013

3.Non communicable Diseases: Obesity, World Health Organization. Available from: www.euro.who.int/en/what-we-do … ble-diseases/obesity Last accessed: May 2013

4.Fransen, J & van Riel P, The Disease Activity Score and the EULAR response criteria, Clinical and Experimental Rheumatology, Nov;35(4):745-57

Related Stories

50 percent of rheumatoid arthritis patients discontinue medication within the first two years

June 13, 2013
Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis (RA) patients discontinue or change therapy within the first year of treatment.

Childbirth increases risk of ACPA-negative rheumatoid arthritis

June 13, 2013
Epidemiological data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate that pregnancy carried to childbirth (parity) increases the risk of ACPA-negative* rheumatoid ...

Abatacept as effective as adalimumab in rheumatoid arthritis

June 12, 2013
Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

RA patients define ideal online tool for physical activity

June 12, 2013
Results of the first study involving RA patients in the development of an internet-based physical activity intervention were presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism.

Obesity is a risk factor for poor remission rates in RA

July 6, 2012
(HealthDay) -- For patients with long-standing rheumatoid arthritis treated with anti-tumor necrosis factor-α (anti-TNFα) therapies, obesity is related to poor remission rates, according to a study published online ...

New method successfully scores joint damage in rheumatoid arthritis

June 12, 2013
A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.

Recommended for you

Prototype equipment can detect rheumatoid arthritis

September 28, 2017
According to a first clinical study published in the scientific journal Photoacoustics, the University of Twente and various European partners have designed a device that shows the difference between healthy fingers and arthritic ...

Improving the recognition of anxiety and depression in rheumatoid arthritis

August 28, 2017
A study conducted by Keele University shows that patients with rheumatoid arthritis who are also suffering with anxiety or depression may avoid talking to their GP about their mental health symptoms.

How you think about your arthritis makes a difference

August 24, 2017
(HealthDay)—How well you cope with knee arthritis depends a lot on your mental outlook, a new study suggests.

Treating arthritis with algae

August 23, 2017
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating arthritis. This is based on a polysaccharide, a long-chain sugar molecule, originating from brown algae. ...

Study shows prevalence of knee osteoarthritis has doubled since World War II

August 14, 2017
The average American today is twice as likely to be diagnosed with knee osteoarthritis than in the years before World War II, Harvard scientists say, but that increase can't be blamed on the reasons most might think.

Researchers find arthritis drug could treat blood cancer patients

August 3, 2017
Blood cancer sufferers could be treated with a simple arthritis drug, scientists at the University of Sheffield have discovered.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.